Esketamine monotherapy is linked to greater 28-day symptom reduction in treatment-resistant depression vs placebo, new research shows.

Esketamine monotherapy demonstrated beneficial antidepressant effects at multiple doses for patients with treatment-resistant depression, according to results of a phase 4 randomized trial published ...

Esketamine, a rapid-onset antidepressant, offers potential advantages for treatment-resistant depression, but its effect on women with perinatal depression is unknown.

The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an inadequate response to at least two oral antidepressants, maker Johnson ...

Budapest, Hungary — A single dose of intravenous esketamine during delivery or caesarean section appears to reduce the risk for postpartum depression (PPD) by more than 50% in the first 6 weeks ...

The FDA has approved esketamine for clinical use in cases of treatment-resistant depression, or depression that fails to respond to more than one antidepressant medication. Esketamine is a ...

SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression Published Jan 21, 2025 8:00am EST ...

Mental health is not just depression, schizophrenia, a mood disorder, anxiety; it has all of the things. We are trying to ...

In March 2019, the VA announced that healthcare providers will now be able to offer the newly approved Esketamine nasal spray, marketed as Spravato, for treatment-resistant depression.. Retired U ...

Johnson & Johnson announced that it has submitted a supplemental new drug application for the approval of esketamine nasal spray as a monotherapy for adults with treatment-resistant depression.If ...

A single low dose injection of esketamine given immediately after childbirth reduces major depressive episodes in individuals with depressive symptoms during pregnancy (prenatal depression), finds ...

Esketamine will soon be available to patients with treatment-resistant depression. While its novel formula achieved FDA approval, some are voicing concerns about limited data.